BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in two upcoming investor conferences this April:
Praxis Precision Medicines to Participate in Upcoming April Conferences
Seeking Alpha / 15 hours ago 1 Views
Comments